The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product...
Date First Received: June 14, 2006
Last Updated: April 15, 2008
Verified by: Astellas Pharma Inc, April 2008
Clinical Trial Phase: Phase 2 | Start Date:
Overall Status: Completed
Estimated Enrollment: 1110
Brief Summary
Condition Keyword(s):
Intervention(s):
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
Study Type: Interventional
Study Design: Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Study Primary Completion Date: March 2007
Intervention(s) in this Clinical Trial
- Drug: YM178
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months
Exclusion Criteria:
- Pregnant and breastfeeding women
- Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Astellas Pharma Inc
Overall Clinical Trial Officials and Contacts
Astellas Pharma Study Chair Astellas Pharma Europe BV
Additional Information
Information obtained from ClinicalTrials.gov on March 18, 2010
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00337090
Study ID Number: 178-CL-044
ClinicalTrials.gov Identifier: NCT00337090
Health Authority: Belgium: Directorate general for the protection of Public health: Medicines
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
